Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS. (Q36146914)

12 August 2017

Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS. (English)

1 reference

12 August 2017

S E Bushnell

1

1 reference

12 August 2017

Z Zhao

2

1 reference

12 August 2017

C C Stebbins

3

1 reference

12 August 2017

D Cadavid

4

1 reference

12 August 2017

A M Buko

5

1 reference

12 August 2017

E T Whalley

6

1 reference

12 August 2017

J A Davis

7

1 reference

12 August 2017

E M Versage

8

1 reference

12 August 2017

J R Richert

9

1 reference

12 August 2017

R C Axtell

10

1 reference

12 August 2017

L Steinman

11

1 reference

12 August 2017

R Medori

12

1 reference

12 August 2017

language of work or name

English

0 references

publication date

9 May 2012

1 reference

12 August 2017

1 reference

12 August 2017

79

1 reference

12 August 2017

6

1 reference

12 August 2017

531-537

1 reference

IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413762

Determinants of interferon β efficacy in patients with multiple sclerosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413762

Type I interferon: friend or foe?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413762

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413762

The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413762

Gene expression analysis of interferon-beta treatment in multiple sclerosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413762

Novel interferon-beta-induced gene expression in peripheral blood cells.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413762

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413762

Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413762

Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413762

Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413762

A guide to the design and analysis of small clinical studies

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413762

Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413762

Defining interferon beta response status in multiple sclerosis patients.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413762

Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413762

Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy

23 September 2018

1 reference

12 December 2020

BAFF is a biological response marker to IFN-beta treatment in multiple sclerosis

1 reference

12 December 2020

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS

1 reference

12 December 2020

Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF, and IL-17AF

1 reference

12 December 2020

Multiplexed analysis of human cytokines by use of the FlowMetrix system

1 reference

12 December 2020

A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses

1 reference

12 December 2020

10.1212/WNL.0B013E318259E123

Identifiers

DOI

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

22573631

1 reference